Kidney Disease, Left Ventricular Hypertrophy
Conditions
Keywords
CKD, LVH, Echo LVH, Chronic Stage 3
Brief summary
Cardiovascular related disease is the main cause of death in patients with kidney disease, and oxidative stress is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries. Allopurinol, a drug used safely in the treatment of gout for many years, has been found to dramatically reduce oxidative stress. It is therefore hoped that it also reduce the thickened heart muscle and stiffened arteries. If it did, it is likely to reduce the appallingly high cardiac death rate in this group of kidney disease patients.
Interventions
DRUGPlacebo
1 capsule, orally for 9 months
DRUGAllopurinol
Allopurinol 300 mg once/day orally, 9 months
Sponsors
A. D. Struthers
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* CKD stage 3 * Echo LVH
Exclusion criteria
* Known heart failure * Patients already on Allopurinol * Patients with gout * Patients with hepatic disease * Contraindications to MRI, including severe claustrophobia * Current immunosuppressive therapy, chlorpropamide, theophylline, 6- mercaptopurine * Malignancy or other life threatening disease * Pregnancy or lactating women * Patients unable to provide written consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective is to see if Allopurinol reduces left ventricular hypertrophy (LVH) in this group of CKD patients | 9 months |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objective is to see if Allopurinol reduces endothelial dysfunction in this group of CKD patients | 9 months |
Countries
United Kingdom
Outcome results
None listed